跳至主要内容
临床试验/NCT05355415
NCT05355415招募中不适用

Adaptive Optics Imaging of Outer Retinal Diseases

Food and Drug Administration (FDA)4 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年8月27日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
4
主要终点
PR cell function

研究概览

简要总结

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

详细描述

Objective

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Study Population: Up to fifty (50) healthy volunteers without eye disease (Cohort 1) and up to fifty (50) affected participants with any type of outer retinal disease (Cohort 2) will be enrolled.

Design: This is a longitudinal study protocol where participants will be imaged with investigational multimodal AO (mAO) retinal imaging systems that include optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) channels over three years. High resolution OCT and SLO videos will be collected while the instruments automatically detect and correct for image distortion caused by ocular aberrations. In general, videos of different retinal cellular structures will be acquired from several retinal locations using various imaging modes.

Outcome Measures: The primary outcomes for this protocol are development of new diagnostic methods and disease biomarkers, investigation of cellular morphological and functional changes due to various outer retinal diseases, and development of new AO clinical endpoints for novel therapies.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Are 21 years of age or older,
  • Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),
  • Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and
  • Have been diagnosed with outer retinal disease or condition (Cohort 2).

排除标准

  • Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),
  • Have visual correction outside of the range +4 diopters (D) to -8 D,
  • Have a history of adverse reaction to mydriatic drops,
  • Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or
  • Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH/NEI AIs.

结局指标

主要结局

PR cell function

时间窗: PR function will be calculated once at the AO imaging session in which PR cells are stimulated. For the reproducibility portion of the study, PR cell function will be quantified three times separated by 1-2 weeks.

Photoreceptor cell (cone) function will be measured from phase changes between inner segment - outer segment junction and cone outer segment tip signals in a sequence of AO-OCT volumes collected during visible light stimulation.

Photoreceptor (PR) density

时间窗: PR density will be calculated once at the AO imaging session in which PRs are the target.

PR density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes or average AOSLO frames.

Retinal pigment epithelial (RPE) cell density

时间窗: RPE cell density will be calculated once at the AO imaging session in which RPE cells are the target.

RPE cell density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes.

RPE cell organelle motility

时间窗: RPE motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times separated by 1-2 weeks.

RPE cell organelle motility will be calculated from the decorrelation time constant for cells segmented from a sequence of AO-OCT volumes.

次要结局

未报告次要终点

研究者

发起方
Food and Drug Administration (FDA)
申办方类型
Fed
责任方
Principal Investigator
主要研究者

Daniel X. Hammer

Deputy Director, Division of Biomedical Physics

Food and Drug Administration (FDA)

研究点 (4)

Loading locations...

相似试验